Ensign Peak Advisors, Inc Janux Therapeutics, Inc. Transaction History
Ensign Peak Advisors, Inc
- $51.2 Billion
- Q1 2025
A detailed history of Ensign Peak Advisors, Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 294,750 shares of JANX stock, worth $7.65 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
294,750
Previous 142,300
107.13%
Holding current value
$7.65 Million
Previous $7.62 Million
4.46%
% of portfolio
0.02%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding JANX
# of Institutions
189Shares Held
57.4MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$290 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$119 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$94.9 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$86.4 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$60.9 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.08B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...